GPRC6A and prostate cancer: Gold nanoparticles with antiandrogen ligands have been developed to target MDR prostate cancer cells with high efficacy of drugs,102 which can selectively target two kinds of receptors including rogen receptors and G‐protein coupled receptors (GPRC6A), while both receptors were usually upregulated in MDR prostate cancer cells.